Jyong Biotech (MENS) Common Equity (2024 - 2025)
Jyong Biotech's (MENS) quarterly Common Equity came in at -$24.9 million in Q4 2025, up 31.8% year-on-year from -$18.9 million in Q4 2024, and down 10.83% quarter-over-quarter from -$22.5 million in Q2 2025.
Jyong Biotech (MENS) Common Equity (2024 - 2025) Analysis & Trends
Jyong Biotech's Common Equity history runs 2 years deep, the most recent figure standing at -$24.9 million for Q4 2025.
- On a quarterly basis, Common Equity rose 31.8% year-over-year to -$24.9 million in Q4 2025; TTM through Dec 2025 was -$24.9 million, a 31.8% increase from a year earlier, with the FY2025 full-year figure at -$24.9 million, up 31.8% from the prior year.
- Common Equity retreated to -$24.9 million in Q4 2025 per MENS's latest filing, from -$22.5 million in the prior quarter.
- Across five years, Common Equity topped out at -$22.5 million in Q2 2025 and bottomed at -$36.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | -24.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.91 Mn |
| Jun 30, 2025 | -22.47 Mn |
| Dec 31, 2024 | -36.52 Mn |